Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Headache

Retrieve available abstracts of 270 articles:
HTML format

Single Articles

    November 2021
  1. VYAS MV, Saposnik G, Lay C
    Migraine and sun avoidance behaviors in Canadian adults.
    Headache. 2021 Nov 2. doi: 10.1111/head.14227.

  2. RAGAB AH, Kishk NA, Hassan A, Yacoub O, et al
    Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study.
    Headache. 2021 Nov 2. doi: 10.1111/head.14231.
    PubMed     Abstract available

    October 2021
  3. YUAN H, Curran JG, Keith SW, Hopkins MM, et al
    Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study.
    Headache. 2021 Oct 3. doi: 10.1111/head.14214.
    PubMed     Abstract available

  4. GALLARDO VJ, Alpuente A, Cerda-Company X, Torres-Ferrus M, et al
    The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish.
    Headache. 2021 Oct 3. doi: 10.1111/head.14225.
    PubMed     Abstract available

  5. PRICE A, Sumner P, Powell G
    Subjective sensory sensitivity and its relationship with anxiety in people with probable migraine.
    Headache. 2021;61:1342-1350.
    PubMed     Abstract available

    September 2021
  6. DODICK DW, Tepper SJ, Ailani J, Pannacciulli N, et al
    Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data.
    Headache. 2021 Sep 30. doi: 10.1111/head.14208.
    PubMed     Abstract available

  7. KLEIN A, Schankin CJ
    Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review.
    Headache. 2021 Sep 27. doi: 10.1111/head.14213.
    PubMed     Abstract available

  8. MARMURA MJ, Diener HC, Cowan RP, Tepper SJ, et al
    Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Headache. 2021 Sep 22. doi: 10.1111/head.14206.
    PubMed     Abstract available

    Memantine for migraine-Big promise but little evidence.
    Headache. 2021;61:1151-1152.

  10. SENG EK
    Stress and migraine: I know it when I see it.
    Headache. 2021;61:1153-1155.

    August 2021
  11. KIM SK, Nikolova S, Schwedt TJ
    Structural aberrations of the brain associated with migraine: A narrative review.
    Headache. 2021 Aug 18. doi: 10.1111/head.14189.
    PubMed     Abstract available

  12. SPIERINGS ELH, Ning X, Ramirez Campos V, Cohen JM, et al
    Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b
    Headache. 2021 Aug 10. doi: 10.1111/head.14196.
    PubMed     Abstract available

  13. VIVES-MESTRES M, Casanova A, Hershey AD, Orr SL, et al
    Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data.
    Headache. 2021 Aug 9. doi: 10.1111/head.14199.
    PubMed     Abstract available

  14. ZHANG N, Woldeamanuel YW
    Medication overuse headache in patients with chronic migraine using cannabis: A case-referent study.
    Headache. 2021 Aug 9. doi: 10.1111/head.14195.
    PubMed     Abstract available

  15. TEPPER SJ, Lucas S, Ashina M, Schwedt TJ, et al
    Timing and durability of response to erenumab in patients with chronic migraine.
    Headache. 2021 Aug 7. doi: 10.1111/head.14193.
    PubMed     Abstract available

  16. SMITH TR, Winner P, Aurora SK, Jeleva M, et al
    STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD((R)) ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.
    Headache. 2021 Aug 7. doi: 10.1111/head.14184.
    PubMed     Abstract available

  17. CARONNA E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P, et al
    Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios.
    Headache. 2021 Aug 7. doi: 10.1111/head.14197.
    PubMed     Abstract available

  18. COHEN F, Friedman BW
    A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis.
    Headache. 2021 Aug 7. doi: 10.1111/head.14185.
    PubMed     Abstract available

  19. MISTRY VM, Morizio PL, Pepin MJ, Bryan WE, et al
    Role of memantine in the prophylactic treatment of episodic migraine: A systematic review.
    Headache. 2021 Aug 5. doi: 10.1111/head.14186.
    PubMed     Abstract available

    July 2021
  20. SAKAI F, Suzuki N, Kim BK, Igarashi H, et al
    Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
    Headache. 2021 Jul 29. doi: 10.1111/head.14169.
    PubMed     Abstract available

  21. SAKAI F, Suzuki N, Kim BK, Tatsuoka Y, et al
    Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
    Headache. 2021 Jul 29. doi: 10.1111/head.14178.
    PubMed     Abstract available

  22. BARBANTI P, Aurilia C, Cevoli S, Egeo G, et al
    Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Headache. 2021 Jul 26. doi: 10.1111/head.14194.
    PubMed     Abstract available

  23. ARCA KN, VanderPluym JH, Halker Singh RB
    Narrative review of neuroimaging in migraine with aura.
    Headache. 2021 Jul 26. doi: 10.1111/head.14191.
    PubMed     Abstract available

  24. THOMSEN AV, Sorensen MT, Ashina M, Hougaard A, et al
    Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity.
    Headache. 2021 Jul 12. doi: 10.1111/head.14187.
    PubMed     Abstract available

  25. SAMPAIO ROCHA-FILHO PA, Albanes Oliveira Bernardo A
    The usefulness of osmophobia for the diagnosis of migraine in children and adolescents.
    Headache. 2021 Jul 4. doi: 10.1111/head.14175.

  26. ISHII R
    Should chronic migraine be defined by eight or more headache days per month?
    Headache. 2021;61:983-984.

  27. WELLS RE, Estave PM, Burch R, Haas N, et al
    The value of the patient perspective in understanding the full burden of migraine.
    Headache. 2021;61:985-987.

  28. MINEN MT, Szperka CL, Kaplan K, Ehrlich A, et al
    Telehealth as a new care delivery model: The headache provider experience.
    Headache. 2021;61:1123-1131.
    PubMed     Abstract available

    June 2021
  29. AILANI J, Burch RC, Robbins MS
    The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
    Headache. 2021 Jun 23. doi: 10.1111/head.14153.
    PubMed     Abstract available

  30. TAKESHIMA T, Sakai F, Hirata K, Imai N, et al
    Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Headache. 2021 Jun 21. doi: 10.1111/head.14138.
    PubMed     Abstract available

  31. RIZZOLI PB, Grazzi L
    Adaptation of the management of chronic migraine patients with medication overuse to the suspension of treatment protocols during the COVID-19 pandemic: Lessons from a tertiary headache center in Milan-6-month results.
    Headache. 2021 Jun 21. doi: 10.1111/head.14140.

  32. BHARADWAJ VN, Porreca F, Cowan RP, Kori S, et al
    A new hypothesis linking oxytocin to menstrual migraine.
    Headache. 2021 Jun 14. doi: 10.1111/head.14152.
    PubMed     Abstract available

  33. BARBANTI P, Fofi L, Grazzi L, Vernieri F, et al
    Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project.
    Headache. 2021 Jun 14. doi: 10.1111/head.14123.
    PubMed     Abstract available

  34. GRAZZI L, Andrasik F, Rizzoli P, Bernstein C, et al
    Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation.
    Headache. 2021 Jun 11. doi: 10.1111/head.14139.
    PubMed     Abstract available

  35. ASHINA M, Cohen JM, Gandhi SK, Du E, et al
    Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
    Headache. 2021 Jun 11. doi: 10.1111/head.14127.
    PubMed     Abstract available

    Could osmophobia be a clinical diagnostic marker for migraine?
    Headache. 2021 Jun 9. doi: 10.1111/head.14148.

  37. KIM BK, Cho S, Kim HY, Chu MK, et al
    Validity and reliability of the self-administered Visual Aura Rating Scale questionnaire for migraine with aura diagnosis: A prospective clinic-based study.
    Headache. 2021 Jun 9. doi: 10.1111/head.14133.
    PubMed     Abstract available

  38. ISHII R, Schwedt TJ, Dumkrieger G, Lalvani N, et al
    Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency.
    Headache. 2021 Jun 3. doi: 10.1111/head.14154.
    PubMed     Abstract available

  39. ESTAVE PM, Beeghly S, Anderson R, Margol C, et al
    Learning the full impact of migraine through patient voices: A qualitative study.
    Headache. 2021 Jun 3. doi: 10.1111/head.14151.
    PubMed     Abstract available

  40. SCHUSTER NM, Gasperi M
    Not just preaching to the CHOIR-A map for improving comprehensive care of patients with chronic migraine and comorbid non-cephalic pain.
    Headache. 2021;61:805-807.

  41. JOSHI S, Tepper SJ, Lucas S, Rasmussen S, et al
    A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management.
    Headache. 2021;61:838-853.
    PubMed     Abstract available

  42. LIANG Z, Thomas L, Jull G, Minto J, et al
    Neck pain associated with migraine does not necessarily reflect cervical musculoskeletal dysfunction.
    Headache. 2021;61:882-894.
    PubMed     Abstract available

  43. NAHMAN-AVERBUCH H, Hershey AD, Peugh JL, King CD, et al
    The promise of mechanistic approaches to understanding how youth with migraine get better-An Editorial to the 2020 Members' Choice Award Paper.
    Headache. 2021;61:803-804.

  44. BARAD MJ, Sturgeon JA, Hong J, Aggarwal AK, et al
    Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study.
    Headache. 2021;61:872-881.
    PubMed     Abstract available

    May 2021
  45. POPOFF E, Johnston K, Croop R, Thiry A, et al
    Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Headache. 2021 May 22. doi: 10.1111/head.14128.
    PubMed     Abstract available

  46. CHIANG CC, Halker Singh R, Lalvani N, Shubin Stein K, et al
    Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study.
    Headache. 2021 May 21. doi: 10.1111/head.14110.
    PubMed     Abstract available

  47. LIPTON RB, Dodick DW, Ailani J, McGill L, et al
    Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
    Headache. 2021 May 20. doi: 10.1111/head.14120.
    PubMed     Abstract available

  48. SAKAI F, Takeshima T, Homma G, Tanji Y, et al
    Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Headache. 2021 May 15. doi: 10.1111/head.14122.
    PubMed     Abstract available

  49. ZIPLOW J
    The importance of studying comorbidities in migraine.
    Headache. 2021;61:697.

    The status of intravenous dihydroergotamine for pediatric headache: Status migrainosus and beyond.
    Headache. 2021;61:698-699.

    April 2021
  51. JAKATE A, Blumenfeld AM, Boinpally R, Butler M, et al
    Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Headache. 2021 Apr 5. doi: 10.1111/head.14095.
    PubMed     Abstract available

  52. YIN JH, Lin YK, Yang CP, Liang CS, et al
    Prevalence and association of lifestyle and medical-, psychiatric-, and pain-related comorbidities in patients with migraine: A cross-sectional study.
    Headache. 2021 Apr 5. doi: 10.1111/head.14106.
    PubMed     Abstract available

  53. AURORA SK, Shrewsbury SB, Ray S, Hindiyeh N, et al
    A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.
    Headache. 2021 Apr 1. doi: 10.1111/head.14099.
    PubMed     Abstract available

  54. BUSE DC, Armand CE, Charleston L 4th, Reed ML, et al
    Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study.
    Headache. 2021 Apr 1. doi: 10.1111/head.14103.
    PubMed     Abstract available

  55. HODGSON SE, Harding AM, Bourke EM, Taylor DM, et al
    A prospective, randomized, double-blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department.
    Headache. 2021 Apr 1. doi: 10.1111/head.14091.
    PubMed     Abstract available

  56. LIPTON RB, Cohen JM, Galic M, Seminerio MJ, et al
    Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
    Headache. 2021;61:662-672.
    PubMed     Abstract available

    Comparing treatments in the emergency department: What works for migraine?
    Headache. 2021;61:567-568.

    March 2021
  58. NAEGEL S, Burow P, Holle D, Stoevesandt D, et al
    Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report.
    Headache. 2021 Mar 29. doi: 10.1111/head.14101.

  59. TRIVEDI M, Dumkrieger G, Chong CD, Dodick DW, et al
    Impact of abuse on migraine-related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research.
    Headache. 2021 Mar 29. doi: 10.1111/head.14100.
    PubMed     Abstract available

  60. SAKAI F, Takeshima T, Tatsuoka Y, Hirata K, et al
    Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Headache. 2021 Mar 25. doi: 10.1111/head.14096.
    PubMed     Abstract available

  61. LIU Y, Xu F, Wheaton AG, Greenlund KJ, et al
    The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015-2016.
    Headache. 2021 Mar 23. doi: 10.1111/head.14087.
    PubMed     Abstract available

  62. VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
    Baseline sleep quality, stress, and depressive symptoms, and subsequent headache occurrence in a six-week prospective cohort study of patients with episodic migraine.
    Headache. 2021 Mar 22. doi: 10.1111/head.14105.
    PubMed     Abstract available

  63. WITTEN A, Marotta D, Cohen-Gadol A
    Developmental innervation of cranial dura mater and migraine headache: A narrative literature review.
    Headache. 2021 Mar 22. doi: 10.1111/head.14102.
    PubMed     Abstract available

  64. COWAN RP, Gross NB, Sweeney MD, Sagare AP, et al
    Evidence that blood-CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen.
    Headache. 2021 Mar 16. doi: 10.1111/head.14088.
    PubMed     Abstract available

    February 2021
  65. ASHINA H, Moskowitz MA
    Shared biological foundations of post-traumatic headache and migraine.
    Headache. 2021 Feb 25. doi: 10.1111/head.14084.

  66. MCGINLEY JS, Wirth RJ, Pavlovic JM, Donoghue S, et al
    Between and within-woman differences in the association between menstruation and migraine days.
    Headache. 2021 Feb 19. doi: 10.1111/head.14058.
    PubMed     Abstract available

  67. MCGINLEY JS, Houts CR, Nishida TK, Buse DC, et al
    Systematic review of outcomes and endpoints in preventive migraine clinical trials.
    Headache. 2021 Feb 18. doi: 10.1111/head.14069.
    PubMed     Abstract available

  68. SHAO Q, Rascati KL, Lawson KA, Wilson JP, et al
    Impact of emergency department opioid use on future health resource utilization among patients with migraine.
    Headache. 2021 Feb 18. doi: 10.1111/head.14071.
    PubMed     Abstract available

  69. KAWATA AK, Shah N, Poon JL, Shaffer S, et al
    Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Headache. 2021 Feb 16. doi: 10.1111/head.14053.
    PubMed     Abstract available

  70. GELFAND AA, Ross AC, Pavitt S, Szperka CL, et al
    Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency? A response.
    Headache. 2021 Feb 5. doi: 10.1111/head.14061.

  71. GELFAND AA, Poland G
    Migraine treatment and COVID-19 vaccines: no cause for concern.
    Headache. 2021 Feb 5. doi: 10.1111/head.14086.
    PubMed     Abstract available

    Once too many: Impact of emergency department opioid use on future health resource utilization among patients with migraine.
    Headache. 2021;61:229-230.

  73. BURCH R
    Outcomes in clinical trials for migraine: What should we measure and who should decide?
    Headache. 2021;61:227-228.

  74. HOUTS CR, McGinley JS, Nishida TK, Buse DC, et al
    Systematic review of outcomes and endpoints in acute migraine clinical trials.
    Headache. 2021;61:263-275.
    PubMed     Abstract available

    January 2021
  75. SLAVIN M, Li H, Khatri M, Frankenfeld C, et al
    Dietary magnesium and migraine in adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2001-2004.
    Headache. 2021 Jan 27. doi: 10.1111/head.14065.
    PubMed     Abstract available

  76. SPECK RM, Yu R, Ford JH, Ayer DW, et al
    Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
    Headache. 2021 Jan 22. doi: 10.1111/head.14031.
    PubMed     Abstract available

  77. NEIVA GR, Meira E Cruz M, Salles C
    Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency?
    Headache. 2021 Jan 20. doi: 10.1111/head.14060.

  78. SCHWEDT TJ, Hentz JG, Sahai-Srivastava S, Spare NM, et al
    Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.
    Headache. 2021 Jan 12. doi: 10.1111/head.14056.
    PubMed     Abstract available

  79. PAVLOVIC JM, Yu JS, Silberstein SD, Reed ML, et al
    Evaluation of the 6-item Identify Chronic Migraine screener in a large medical group.
    Headache. 2021 Jan 9. doi: 10.1111/head.14035.
    PubMed     Abstract available

  80. LIAMPAS I, Mylonas KS, Brotis A, Dervenis P, et al
    Serum lipid abnormalities in migraine: A meta-analysis of observational studies.
    Headache. 2021 Jan 4. doi: 10.1111/head.14039.
    PubMed     Abstract available

  81. O'BRIEN HL, Halker Singh RB
    Breaking down barriers to care: Understanding migraine knowledge gaps among women's healthcare providers.
    Headache. 2021;61:7-8.

  82. KARVOUNIDES D, Marzouk M, Ross AC, VanderPluym JH, et al
    The intersection of COVID-19, school, and headaches: Problems and solutions.
    Headache. 2021;61:190-201.
    PubMed     Abstract available

    December 2020
  83. OSWALD JC, Schuster NM
    A randomized, double-dummy, emergency department-based study of greater occipital nerve block with bupivacaine versus intravenous metoclopramide for treatment of migraine: A comment.
    Headache. 2020 Dec 31. doi: 10.1111/head.14044.

  84. SPECTOR AR, Kerkow JF, Collins TA
    Sleep terrors prodromal for migraine headaches responsive to galcanezumab: A case report.
    Headache. 2020 Dec 31. doi: 10.1111/head.14055.

  85. CONNELLY MA, Boorigie ME
    Feasibility of using "SMARTER" methodology for monitoring precipitating conditions of pediatric migraine episodes.
    Headache. 2020 Dec 31. doi: 10.1111/head.14028.
    PubMed     Abstract available

  86. CHENG V, Billups SJ, Saseen JJ
    Prescribing practices of migraine-specific pharmacotherapy associated with emergency department use for migraine.
    Headache. 2020 Dec 30. doi: 10.1111/head.14029.
    PubMed     Abstract available

  87. VERHAAK AMS, Williamson A, Johnson A, Murphy A, et al
    Migraine diagnosis and treatment: A knowledge and needs assessment of women's healthcare providers.
    Headache. 2020 Dec 30. doi: 10.1111/head.14027.
    PubMed     Abstract available

  88. PRESSMAN AR, Buse DC, Jacobson AS, Vaidya SJ, et al
    The migraine signature study: Methods and baseline results.
    Headache. 2020 Dec 23. doi: 10.1111/head.14033.
    PubMed     Abstract available

  89. BURCH R, Rizzoli P, Loder E
    The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys.
    Headache. 2020 Dec 21. doi: 10.1111/head.14024.
    PubMed     Abstract available

  90. HAGAN KK, Li W, Mostofsky E, Bertisch SM, et al
    Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine.
    Headache. 2020 Dec 21. doi: 10.1111/head.14037.
    PubMed     Abstract available

  91. HERSHEY AD, Lin T, Gruper Y, Harris D, et al
    Remote electrical neuromodulation for acute treatment of migraine in adolescents.
    Headache. 2020 Dec 21. doi: 10.1111/head.14042.
    PubMed     Abstract available

  92. BARBANTI P, Aurilia C, Egeo G, Fofi L, et al
    Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Headache. 2020 Dec 18. doi: 10.1111/head.14032.
    PubMed     Abstract available

  93. TORABI SJ, Kasle DA, Savoca EL, Gottschalk CH, et al
    Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population.
    Headache. 2020 Dec 18. doi: 10.1111/head.14040.
    PubMed     Abstract available

  94. LIPTON RB, Buse DC, Dodick DW, Schwedt TJ, et al
    Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
    Headache. 2020 Dec 16. doi: 10.1111/head.14018.
    PubMed     Abstract available

  95. SMITH M, Nakamoto M, Crocker J, Tiffany Morden F, et al
    Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey.
    Headache. 2020 Dec 14. doi: 10.1111/head.14030.
    PubMed     Abstract available

  96. DIENER HC, Marmura MJ, Tepper SJ, Cowan R, et al
    Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Headache. 2020 Dec 13. doi: 10.1111/head.14036.
    PubMed     Abstract available

    November 2020
  97. GELFAND AA, Pavitt S, Ross AC, Szperka CL, et al
    Later high school start time is associated with lower migraine frequency in adolescents.
    Headache. 2020 Nov 25. doi: 10.1111/head.14016.
    PubMed     Abstract available

  98. NAHMAN-AVERBUCH H, Thomas PL, Schneider VJ 2nd, Chamberlin LA, et al
    Spatial aspects of pain modulation are not disrupted in adolescents with migraine.
    Headache. 2020 Nov 24. doi: 10.1111/head.14017.
    PubMed     Abstract available

  99. TIRITICCO M, Vanotti A, Mantica D, Coppola A, et al
    Migraine With Exclusive Olfactory Aura: Case Report and Literature Review.
    Headache. 2020 Nov 18. doi: 10.1111/head.14014.
    PubMed     Abstract available

  100. MINEN MT, Adhikari S, Padikkala J, Tasneem S, et al
    Smartphone-Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial.
    Headache. 2020 Nov 16. doi: 10.1111/head.14010.
    PubMed     Abstract available

  101. LIPTON RB, Cohen JM, Bibeau K, Galic M, et al
    Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
    Headache. 2020 Nov 11. doi: 10.1111/head.13997.
    PubMed     Abstract available

  102. POLK AN, Protti TA, Smitherman TA
    Allodynia and Disability in Migraine: The Mediating Role of Stress.
    Headache. 2020 Nov 9. doi: 10.1111/head.14012.
    PubMed     Abstract available

  103. DODICK DW, Gottschalk C, Cady R, Hirman J, et al
    Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.
    Headache. 2020 Nov 9. doi: 10.1111/head.14007.
    PubMed     Abstract available

  104. PILATI L, Battaglia G, Di Stefano V, Di Marco S, et al
    Migraine and Sport in a Physically Active Population of Students: Results of a Cross-Sectional Study.
    Headache. 2020 Nov 7. doi: 10.1111/head.14015.
    PubMed     Abstract available

  105. GILL K, Chia VM, Hernandez RK, Navetta M, et al
    Rates of Vascular Events in Patients With Migraine: A MarketScan((R)) Database Retrospective Cohort Study.
    Headache. 2020 Nov 3. doi: 10.1111/head.14001.
    PubMed     Abstract available

  106. BUSE DC, McGinley JS, Lipton RB
    Predicting the Future of Migraine Attack Prediction.
    Headache. 2020;60:2125-2128.

  107. VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
    The Sleep - Migraine Enigma: A Comment.
    Headache. 2020;60:2610.

  108. FORD JH, Kurth T, Starling AJ, Ayer DW, et al
    Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Headache. 2020;60:2304-2319.
    PubMed     Abstract available

    October 2020
  109. ANDERSON CC, Ray CA, Butler MR, Darken RS, et al
    Effects of Procedural Discomfort and Expectation of Benefit on Therapy Continuation in Chronic Migraine Patients Treated With OnabotulinumtoxinA.
    Headache. 2020 Oct 31. doi: 10.1111/head.14008.
    PubMed     Abstract available

  110. BOLAY H, Ozge A, Uluduz D, Baykan B, et al
    Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?
    Headache. 2020 Oct 30. doi: 10.1111/head.13998.
    PubMed     Abstract available

  111. KRYMCHANTOWSKI A, Jevoux C, Silva-Neto RP, Krymchantowski AG, et al
    Migraine Treatment in Emergency Departments of Brazil: A Retrospective Study of 2 Regions.
    Headache. 2020 Oct 27. doi: 10.1111/head.13999.
    PubMed     Abstract available

  112. BLUMENFELD AM, Silberstein SD
    Response to "Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice".
    Headache. 2020 Oct 27. doi: 10.1111/head.13996.

  113. SMITHERMAN TA, Tietjen GE, Schuh K, Skljarevski V, et al
    Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
    Headache. 2020 Oct 16. doi: 10.1111/head.13970.
    PubMed     Abstract available

  114. BUSE DC, Reed ML, Fanning KM, Bostic RC, et al
    Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Headache. 2020 Oct 14. doi: 10.1111/head.13966.
    PubMed     Abstract available

  115. TU S, Liew D, Ademi Z, Owen AJ, et al
    The Health and Productivity Burden of Migraines in Australia.
    Headache. 2020 Oct 7. doi: 10.1111/head.13969.
    PubMed     Abstract available

  116. HOLSTEEN KK, Hittle M, Barad M, Nelson LM, et al
    Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures.
    Headache. 2020 Oct 6. doi: 10.1111/head.13960.
    PubMed     Abstract available

  117. BEUTHIN J, Veronesi M, Grosberg B, Evans RW, et al
    Gluten-Free Diet and Migraine.
    Headache. 2020 Oct 6. doi: 10.1111/head.13993.
    PubMed     Abstract available

  118. GHANSHANI S, Chen C, Lin B, Duan L, et al
    Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
    Headache. 2020 Oct 5. doi: 10.1111/head.13959.
    PubMed     Abstract available

  119. TOMKINS E, Craven A, Ruttledge M
    Migraine and Headache Care in the Republic of Ireland: History and a Vision for the Future Influenced by the COVID-19 Pandemic.
    Headache. 2020 Oct 3. doi: 10.1111/head.13985.
    PubMed     Abstract available

    September 2020
  120. SWART ECS, Good CB, Henderson R, Manolis C, et al
    Identifying Outcome Measures for Migraine Value-Based Contracting Using the Delphi Method.
    Headache. 2020 Sep 30. doi: 10.1111/head.13978.
    PubMed     Abstract available

  121. CHENG S, Jenkins B, Limberg N, Hutton E, et al
    Erenumab in Chronic Migraine: An Australian Experience.
    Headache. 2020 Sep 29. doi: 10.1111/head.13968.
    PubMed     Abstract available

  122. HAMILTON KT, Halker Singh RB, Ailani J, Butterfield RJ, et al
    Migraine Treatment in Pregnancy: An American Headache Society Survey.
    Headache. 2020 Sep 29. doi: 10.1111/head.13974.

  123. FRIEDMAN BW, Irizarry E, Williams A, Solorzano C, et al
    A Randomized, Double-Dummy, Emergency Department-Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine.
    Headache. 2020 Sep 27. doi: 10.1111/head.13961.
    PubMed     Abstract available

  124. QUINTAS M, Neto JL, Sequeiros J, Sousa A, et al
    Going Deep into Synaptic Vesicle Machinery Genes and Migraine Susceptibility - A Case-Control Association Study.
    Headache. 2020 Sep 26. doi: 10.1111/head.13957.
    PubMed     Abstract available

  125. MARTINS B, Costa A
    Migraine Improvement During COVID-19 Pandemic - A Case Report on the Wonders of a Mask.
    Headache. 2020 Sep 23. doi: 10.1111/head.13964.

  126. ROBBLEE J, Devick KL, Mendez N, Potter J, et al
    Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Headache. 2020 Sep 13. doi: 10.1111/head.13951.
    PubMed     Abstract available

  127. VIVES-MESTRES M, Casanova A, Buse DC, Donoghue S, et al
    Patterns of Perceived Stress Throughout the Migraine Cycle: A Longitudinal Cohort Study Using Daily Prospective Diary Data.
    Headache. 2020 Sep 12. doi: 10.1111/head.13943.
    PubMed     Abstract available

  128. BHERING MARTINS L, Silva de Miranda A, Rodrigues AMDS, Braga Tibaes JR, et al
    Altered Serum Levels of Renin-Angiotensin System Markers in Migraine.
    Headache. 2020 Sep 2. doi: 10.1111/head.13949.
    PubMed     Abstract available

  129. GELFAND AA, Ross AC, Irwin SL, Greene KA, et al
    Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.
    Headache. 2020;60:1712-1721.
    PubMed     Abstract available

  130. TOPTAN T, Aktan C, Basari A, Bolay H, et al
    Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom.
    Headache. 2020;60:1788-1792.
    PubMed     Abstract available

    Persistent Headache and Persistent Anosmia Associated With COVID-19.
    Headache. 2020;60:1797-1799.

  132. PORTA-ETESSAM J, Matias-Guiu JA, Gonzalez-Garcia N, Gomez Iglesias P, et al
    Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals.
    Headache. 2020;60:1697-1704.
    PubMed     Abstract available

  133. BOBKER SM, Robbins MS
    COVID-19 and Headache: A Primer for Trainees.
    Headache. 2020;60:1806-1811.
    PubMed     Abstract available

  134. LIPTON RB, Seng EK, Chu MK, Reed ML, et al
    The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
    Headache. 2020;60:1683-1696.
    PubMed     Abstract available

    August 2020
  135. HOUTS CR, Wirth RJ, McGinley JS, Cady R, et al
    Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.
    Headache. 2020 Aug 30. doi: 10.1111/head.13946.
    PubMed     Abstract available

  136. THEROUX LM, Cappa R, Mendoza A, Mallawaarachchi I, et al
    Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Headache. 2020 Aug 27. doi: 10.1111/head.13937.
    PubMed     Abstract available

  137. LAW EF, Blume H, Palermo TM
    Longitudinal Impact of Parent Factors in Adolescents With Migraine and Tension-Type Headache.
    Headache. 2020 Aug 27. doi: 10.1111/head.13939.
    PubMed     Abstract available

  138. BARBANTI P, Brighina F, Egeo G, Di Stefano V, et al
    Migraine as a Cortical Brain Disorder.
    Headache. 2020 Aug 26. doi: 10.1111/head.13935.
    PubMed     Abstract available

  139. BROESSNER G, Reuter U, Bonner JH, Dodick DW, et al
    The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving >/=50%, >/=75%, and 100% Response.
    Headache. 2020 Aug 26. doi: 10.1111/head.13929.
    PubMed     Abstract available

  140. RIESCO N, Cernuda-Morollon E, Martinez-Camblor P, Perez-Pereda S, et al
    Peripheral, Interictal Serum S100B Levels are Not Increased in Chronic Migraine Patients.
    Headache. 2020 Aug 17. doi: 10.1111/head.13919.
    PubMed     Abstract available

  141. SCHAETZ L, Rimner T, Pathak P, Fang J, et al
    Employee and Employer Benefits From a Migraine Management Program: Disease Outcomes and Cost Analysis.
    Headache. 2020 Aug 16. doi: 10.1111/head.13933.
    PubMed     Abstract available

  142. BERMAN G, Croop R, Kudrow D, Halverson P, et al
    Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Headache. 2020 Aug 16. doi: 10.1111/head.13930.
    PubMed     Abstract available

  143. RUSCHEWEYH R, Athwal B, Gryglas-Dworak A, Frattale I, et al
    Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Headache. 2020 Aug 14. doi: 10.1111/head.13925.
    PubMed     Abstract available

  144. KOW CS, Hasan SS
    The use of pharmacological preventive therapy for migraine with weight gain potential amid COVID-19 pandemic.
    Headache. 2020 Aug 13. doi: 10.1111/head.13945.
    PubMed     Abstract available

  145. PINHEIRO CF, Moraes R, Carvalho GF, Sestari L, et al
    The Influence of Photophobia on Postural Control in Patients With Migraine.
    Headache. 2020 Aug 13. doi: 10.1111/head.13908.
    PubMed     Abstract available

  146. NGUYEN BN, Singh S, Downie LE, McKendrick AM, et al
    Migraine Screening in Primary Eye Care Practice: Current Behaviors and the Impact of Clinician Education.
    Headache. 2020 Aug 7. doi: 10.1111/head.13920.
    PubMed     Abstract available

  147. CAPE S
    Access to Migraine Treatments in Ontario, Canada: A Review of the Ontario Drug Benefit Program.
    Headache. 2020 Aug 5. doi: 10.1111/head.13918.
    PubMed     Abstract available

  148. PEARL TA, Dumkrieger G, Chong CD, Dodick DW, et al
    Impact of Depression and Anxiety Symptoms on Patient-Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR).
    Headache. 2020 Aug 4. doi: 10.1111/head.13911.
    PubMed     Abstract available

  149. SPECK RM, Collins EM, Lombard L, Ayer DW, et al
    A Qualitative Study to Assess the Content Validity of the 24-Hour Migraine Quality of Life Questionnaire in Patients with Migraine.
    Headache. 2020 Aug 3. doi: 10.1111/head.13915.
    PubMed     Abstract available

  150. ROGERS DG, Bond DS, Bentley JP, Smitherman TA, et al
    Objectively Measured Physical Activity in Migraine as a Function of Headache Activity.
    Headache. 2020 Aug 2. doi: 10.1111/head.13921.
    PubMed     Abstract available

    July 2020
  151. WATTIEZ AS, O'Shea SA, Ten Eyck P, Sowers LP, et al
    Patients With Vestibular Migraine are More Likely to Have Occipital Headaches than those With Migraine Without Vestibular Symptoms.
    Headache. 2020 Jul 25. doi: 10.1111/head.13898.
    PubMed     Abstract available

  152. FORBES RB, McCarron M, Cardwell CR
    Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis.
    Headache. 2020 Jul 15. doi: 10.1111/head.13907.
    PubMed     Abstract available

  153. CAROLI A, Klan T, Gaul C, Kubik SU, et al
    Types of Triggers in Migraine - Factor Structure of the Headache Triggers Sensitivity and Avoidance Questionnaire and Development of a New Short Form (HTSAQ-SF).
    Headache. 2020 Jul 11. doi: 10.1111/head.13896.
    PubMed     Abstract available

  154. TEPPER SJ, Vasudeva R, Krege JH, Rathmann SS, et al
    Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Headache. 2020 Jul 7. doi: 10.1111/head.13897.
    PubMed     Abstract available

  155. LIAMPAS I, Siokas V, Mentis AA, Aloizou AM, et al
    Serum Homocysteine, Pyridoxine, Folate, and Vitamin B12 Levels in Migraine: Systematic Review and Meta-Analysis.
    Headache. 2020 Jul 2. doi: 10.1111/head.13892.
    PubMed     Abstract available

  156. MINEN MT, Jaran J, Boyers T, Corner S, et al
    Understanding What People With Migraine Consider to be Important Features of Migraine Tracking: An Analysis of the Utilization of Smartphone-Based Migraine Tracking With a Free-Text Feature.
    Headache. 2020;60:1402-1414.
    PubMed     Abstract available

  157. SUZUKI K, Fujita H, Hirata K
    Parkinson's Disease and Headache: Is there a Relevant Relationship?
    Headache. 2020;60:1440-1441.

    June 2020
  158. BURSTEIN R, Blumenfeld AM, Silberstein SD, Manack Adams A, et al
    Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review.
    Headache. 2020 Jun 30. doi: 10.1111/head.13849.
    PubMed     Abstract available

  159. DANNO D, Wolf J, Ishizaki K, Kikui S, et al
    Cranial Autonomic Symptoms of Migraine in Japan: Prospective Study of 373 Migraine Patients at a Tertiary Headache Center.
    Headache. 2020 Jun 27. doi: 10.1111/head.13888.
    PubMed     Abstract available

  160. JAKATE A, Boinpally R, Butler M, Lu K, et al
    Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
    Headache. 2020 Jun 23. doi: 10.1111/head.13862.
    PubMed     Abstract available

  161. KARSAN N, Bose PR, O'Daly O, Zelaya FO, et al
    Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack.
    Headache. 2020 Jun 22. doi: 10.1111/head.13865.
    PubMed     Abstract available

  162. RUSSO A, Silvestro M, Trojsi F, Bisecco A, et al
    Cognitive Networks Disarrangement in Patients With Migraine Predicts Cutaneous Allodynia.
    Headache. 2020 Jun 13. doi: 10.1111/head.13860.
    PubMed     Abstract available

  163. PORTA-ETESSAM J, Gonzalez-Garcia N, Matias-Guiu JA, Montero-Escribano P, et al
    Should we adapt the prescription criteria for specific treatments for migraine due to the Covid-19 pandemic?
    Headache. 2020 Jun 11. doi: 10.1111/head.13880.
    PubMed     Abstract available

  164. SINGH J, Ali A
    Headache as the Presenting Symptom in 2 Patients with COVID-19 and a History of Migraine: 2 Case Reports.
    Headache. 2020 Jun 10. doi: 10.1111/head.13890.
    PubMed     Abstract available

  165. CHAN TLH, Cowan RP, Woldeamanuel YW
    Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis.
    Headache. 2020 Jun 9. doi: 10.1111/head.13858.
    PubMed     Abstract available

  166. LOMBARD L, Ye W, Nichols R, Jackson J, et al
    A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment.
    Headache. 2020 Jun 8. doi: 10.1111/head.13835.
    PubMed     Abstract available

  167. ROBBINS L, Tropp-Bluestone M
    Evolution and Migraine.
    Headache. 2020 Jun 8. doi: 10.1111/head.13837.

  168. PEREZ-PEREDA S, Gonzalez-Quintanilla V, Madera J, Pascual J, et al
    Chronic Migraine With Apparent Loss of Response to Onabotulinum Toxin Type A Due to Local Nitroglycerin Treatment for an Anal Fissure: A Case Report.
    Headache. 2020 Jun 3. doi: 10.1111/head.13863.
    PubMed     Abstract available

  169. KEARNEY E, Collins T, Sengupta S
    De Novo Visual Aura Onset in a Migraineur on Galcanezumab-Gnlm.
    Headache. 2020 Jun 1. doi: 10.1111/head.13855.

  170. TEPPER D
    Lasmiditan for the acute treatment of migraine.
    Headache. 2020;60:1225-1226.

  171. VIGANO A, Mancini V, Mastria G, Di Piero V, et al
    Is it Useful to Do a Taxonomy of Complex Visual Symptoms in Migraine? A Comment on Coining the Pablo Picasso Syndrome.
    Headache. 2020;60:1200-1201.

  172. ALI A
    Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot.
    Headache. 2020;60:1183-1186.
    PubMed     Abstract available

    May 2020
  173. RUSSO A, Lavorgna L, Silvestro M, Abbadessa G, et al
    Readability Analysis of Online Headache and Migraine Information.
    Headache. 2020 May 28. doi: 10.1111/head.13818.
    PubMed     Abstract available

  174. GVANTSELADZE K, Do TP, Hansen JM, Shapiro RE, et al
    The Stereotypical Image of a Person With Migraine According to Mass Media.
    Headache. 2020 May 27. doi: 10.1111/head.13846.
    PubMed     Abstract available

  175. HINDIYEH NA, Zhang N, Farrar M, Banerjee P, et al
    The Role of Diet and Nutrition in Migraine Triggers and Treatment: A Systematic Literature Review.
    Headache. 2020 May 25. doi: 10.1111/head.13836.
    PubMed     Abstract available

  176. PELLESI L, Do TP, Ashina H, Ashina M, et al
    Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
    Headache. 2020 May 21. doi: 10.1111/head.13843.
    PubMed     Abstract available

  177. GIBBS SN, Shah S, Deshpande CG, Bensink ME, et al
    United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
    Headache. 2020 May 5. doi: 10.1111/head.13829.
    PubMed     Abstract available

  178. SILVESTRO M, Tessitore A, Scotto di Clemente F, Tedeschi G, et al
    Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
    Headache. 2020 May 2. doi: 10.1111/head.13832.
    PubMed     Abstract available

  179. WELLS RE, Strauss LD
    The Value of Headache-Specific Recommendations During COVID-19.
    Headache. 2020;60:820-823.

  180. EGHTESADI M, Marquis-Gravel G
    Rethinking Our Cardiovascular Risk Assessment in the Younger Female Migraine Population.
    Headache. 2020;60:994-997.

    April 2020
  181. LIAMPAS I, Siokas V, Brotis A, Vikelis M, et al
    Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis.
    Headache. 2020 Apr 30. doi: 10.1111/head.13828.
    PubMed     Abstract available

  182. GRAZZI L, Rizzoli P
    The Adaptation of Management of Chronic Migraine Patients With Medication Overuse to the Suspension of Treatment Protocols During the COVID-19 Pandemic: Lessons From a Tertiary Headache Center in Milan, Italy.
    Headache. 2020 Apr 30. doi: 10.1111/head.13825.

  183. BEGASSE DE DHAEM O, Gharedaghi MH, Rizzoli P
    Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice.
    Headache. 2020 Apr 25. doi: 10.1111/head.13823.
    PubMed     Abstract available

  184. NAHMAN-AVERBUCH H, Schneider VJ 2nd, Chamberlin LA, Kroon Van Diest AM, et al
    Alterations in Brain Function After Cognitive Behavioral Therapy for Migraine in Children and Adolescents.
    Headache. 2020 Apr 23. doi: 10.1111/head.13814.
    PubMed     Abstract available

  185. HAMMOND NG, Colman I
    The Role of Positive Health Behaviors in the Relationship Between Early Life Stress and Migraine.
    Headache. 2020 Apr 22. doi: 10.1111/head.13808.
    PubMed     Abstract available

  186. HOMMEL KA, Carmody J, Hershey AD, Holbein C, et al
    Digital Therapeutic Self-Management Intervention in Adolescents With Migraine: Feasibility and Preliminary Efficacy of "Migraine Manager".
    Headache. 2020 Apr 22. doi: 10.1111/head.13805.
    PubMed     Abstract available

  187. ALBANES OLIVEIRA BERNARDO A, Lys Medeiros F, Sampaio Rocha-Filho PA
    Osmophobia and Odor-Triggered Headaches in Children and Adolescents: Prevalence, Associated Factors, and Importance in the Diagnosis of Migraine.
    Headache. 2020 Apr 15. doi: 10.1111/head.13806.
    PubMed     Abstract available

    Inflammatory Milieu May Trigger Metabolic Changes in Migraine Attacks.
    Headache. 2020 Apr 15. doi: 10.1111/head.13799.

  189. FREDERIKSEN SD, Bekker-Nielsen Dunbar M, Snoer AH, Deen M, et al
    Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis.
    Headache. 2020 Apr 15. doi: 10.1111/head.13802.
    PubMed     Abstract available

  190. VIEIRA A, van der Linde I, Bright P, Wilkins A, et al
    Preference for Lighting Chromaticity in Migraine With Aura.
    Headache. 2020 Apr 13. doi: 10.1111/head.13801.
    PubMed     Abstract available

  191. SILVESTRO M, Tessitore A, Tedeschi G, Russo A, et al
    Migraine in the Time of COVID-19.
    Headache. 2020 Apr 8. doi: 10.1111/head.13803.

  192. MINEN MT, Robbins MS, Loder E, Nahas S, et al
    Addressing the Crisis of Diagnosis and Management of Migraine in Primary Care: A Summary of the American Headache Society FrontLine Primary Care Advisory Board.
    Headache. 2020 Apr 8. doi: 10.1111/head.13797.

  193. TIETJEN GE, Maly EF
    Migraine and Ischemic Stroke in Women. A Narrative Review.
    Headache. 2020 Apr 4. doi: 10.1111/head.13796.
    PubMed     Abstract available

    March 2020
  194. FERNANDES L, Khan N, Dobson J, Randall M, et al
    Multiple Cranial Nerve Blocks as an Alternative Preventative Therapy for Chronic Migraine.
    Headache. 2020 Mar 30. doi: 10.1111/head.13792.
    PubMed     Abstract available

  195. SZPERKA CL, Ailani J, Barmherzig R, Klein BC, et al
    Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to Insurers.
    Headache. 2020 Mar 30. doi: 10.1111/head.13810.
    PubMed     Abstract available

  196. MINEN MT, Jalloh A, Begasse de Dhaem O, Seng EK, et al
    Behavioral Therapy Preferences in People With Migraine.
    Headache. 2020 Mar 23. doi: 10.1111/head.13790.
    PubMed     Abstract available

  197. MAKAR GS, Siegal T, Syrow L
    Stroke-Like Migraine Attacks After Radiation Therapy (SMART) Syndrome: A Rare, Reversible Complication of Radiation Therapy.
    Headache. 2020 Mar 23. doi: 10.1111/head.13786.

  198. GEORGE KM, Folsom AR, Sharrett AR, Mosley TH, et al
    Migraine Headache and Risk of Dementia in the Atherosclerosis Risk in Communities Neurocognitive Study.
    Headache. 2020 Mar 22. doi: 10.1111/head.13794.
    PubMed     Abstract available

  199. RODRIGUEZ-CASTRO E, Lagorio AN, Bejarano-Garcia A, Aguiar P, et al
    Prolonged Migraine Stuttering Aura: Structural, Functional, and Video Neuroimaging Study of an Atypical Migraine Aura. A Case Report.
    Headache. 2020 Mar 5. doi: 10.1111/head.13780.
    PubMed     Abstract available

    February 2020
  200. CRAWFORD MR, Luik AI, Espie CA, Taylor HL, et al
    Digital Cognitive Behavioral Therapy for Insomnia in Women With Chronic Migraines.
    Headache. 2020 Feb 28. doi: 10.1111/head.13777.
    PubMed     Abstract available

  201. FALLA K, Ronksley P, Noel M, Orr SL, et al
    Internalizing Symptoms in Pediatric Migraine: A Systematic Review Protocol.
    Headache. 2020 Feb 25. doi: 10.1111/head.13778.
    PubMed     Abstract available

  202. GRAZZI L, Rizzoli P
    Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!
    Headache. 2020 Feb 25. doi: 10.1111/head.13776.

  203. ORNELLO R, Frattale I, Pistoia F, Sacco S, et al
    Erenumab Plus Subcutaneous Immunoglobulin in a Patient With Comorbid Chronic Migraine and Myasthenia Gravis.
    Headache. 2020 Feb 25. doi: 10.1111/head.13779.

  204. DODICK DW, Lipton RB, Ailani J, Halker Singh RB, et al
    Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Headache. 2020 Feb 19. doi: 10.1111/head.13766.
    PubMed     Abstract available

  205. CARONNA E, Gallardo VJ, Fonseca E, Gomez-Galvan JB, et al
    How Does Migraine Change After 10 Years? A Clinical Cohort Follow-Up Analysis.
    Headache. 2020 Feb 18. doi: 10.1111/head.13774.
    PubMed     Abstract available

  206. GOLLION C, Arribarat G, Ruidavets JB, Fabre N, et al
    Neuromelanin Locus Coeruleus MRI Contrast in Migraine With Aura.
    Headache. 2020 Feb 17. doi: 10.1111/head.13771.
    PubMed     Abstract available

  207. STUBBERUD A, Tronvik E, Olsen A, Gravdahl G, et al
    Biofeedback Treatment App for Pediatric Migraine: Development and Usability Study.
    Headache. 2020 Feb 13. doi: 10.1111/head.13772.
    PubMed     Abstract available

  208. LEWIS R, Ruiz A, Monteith T
    Reversible Lesion of the Corpus Callosum in a Patient With Migraine With Aura: A Case Study.
    Headache. 2020 Feb 11. doi: 10.1111/head.13768.
    PubMed     Abstract available

  209. WINNER PK, Kabbouche M, Yonker M, Wangsadipura V, et al
    A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
    Headache. 2020 Feb 9. doi: 10.1111/head.13754.
    PubMed     Abstract available

  210. ORR SL, Turner A, Kabbouche MA, Horn PS, et al
    The Profile and Prognosis of Youth With Status Migrainosus: Results From an Observational Study.
    Headache. 2020 Feb 7. doi: 10.1111/head.13767.
    PubMed     Abstract available

  211. ZHANG DG, Amin FM, Guo S, Vestergaard MB, et al
    Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura.
    Headache. 2020 Feb 7. doi: 10.1111/head.13760.
    PubMed     Abstract available

  212. LEE YH, Huang IH, Kang YN
    Do Treatment Strategies of Fremanezumab Have Similar Effect on Migraine?
    Headache. 2020;60:473-475.

    January 2020
  213. HOUGAARD A, Younis S, Iljazi A, Sugimoto K, et al
    Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura.
    Headache. 2020 Jan 29. doi: 10.1111/head.13753.
    PubMed     Abstract available

  214. RIGGINS N, Ehrlich A, Sawhney H, Dapkus L, et al
    Retrospective Chart Review of Intravenous Valproate Sodium as a Preventive Treatment for Patients With Chronic Migraine.
    Headache. 2020 Jan 27. doi: 10.1111/head.13756.
    PubMed     Abstract available

  215. PURDY RA
    Migraine and Other Primary Headaches.
    Headache. 2020 Jan 26. doi: 10.1111/head.13750.

  216. MINEN MT, Sahyoun G, Gopal A, Levitan V, et al
    A Pilot Randomized Controlled Trial to Assess the Impact of Motivational Interviewing on Initiating Behavioral Therapy for Migraine.
    Headache. 2020 Jan 24. doi: 10.1111/head.13738.
    PubMed     Abstract available

  217. DIENER HC
    The Risks or Lack Thereof of Migraine Treatments in Vascular Disease.
    Headache. 2020 Jan 22. doi: 10.1111/head.13749.
    PubMed     Abstract available

  218. CHONG CD, Aguilar M, Schwedt TJ
    Altered Hypothalamic Region Covariance in Migraine and Cluster Headache: A Structural MRI Study.
    Headache. 2020 Jan 22. doi: 10.1111/head.13742.
    PubMed     Abstract available

  219. SPROUSE BLUM AS, Couperus CJ, Rosen BJ, Haskin-Leahy LF, et al
    Familial "Diplegic" Migraine - Description of a Family With a Novel CACNA1A Mutation.
    Headache. 2020 Jan 22. doi: 10.1111/head.13741.
    PubMed     Abstract available

  220. PEARL TA, Dumkrieger G, Chong CD, Dodick DW, et al
    Sensory Hypersensitivity Symptoms in Migraine With vs Without Aura: Results From the American Registry for Migraine Research.
    Headache. 2020 Jan 22. doi: 10.1111/head.13745.
    PubMed     Abstract available

  221. FALKENBERG K, Ronde Bjerg H, Yamani N, Olesen J, et al
    Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers.
    Headache. 2020 Jan 16. doi: 10.1111/head.13747.
    PubMed     Abstract available

  222. D'AMICO D, Grazzi L, Grignani E, Leonardi M, et al
    HEADWORK Questionnaire: Why Do We Need a New Tool to Assess Work-Related Disability in Patients With Migraine?
    Headache. 2020 Jan 13. doi: 10.1111/head.13735.
    PubMed     Abstract available

  223. DARSEY M, Kyros T, Wang V, Rizzoli PB, et al
    Intranasal 3% Tetracaine Plus 0.05% Oxymetazoline in the Management of Status Migrainosus.
    Headache. 2020 Jan 9. doi: 10.1111/head.13739.

  224. SCOTT BR, Uomoto JM, Barry ES
    Impact of Pre-Existing Migraine and Other Co-Morbid or Co-Occurring Conditions on Presentation and Clinical Course Following Deployment-Related Concussion.
    Headache. 2020 Jan 3. doi: 10.1111/head.13709.
    PubMed     Abstract available

  225. AILANI J, Lipton RB, Hutchinson S, Knievel K, et al
    Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
    Headache. 2020;60:141-152.
    PubMed     Abstract available

  226. NYE B, Thadani V
    Migraine and Driving.
    Headache. 2020;60:13-14.

  227. RAPOPORT AM, Lin T, Tepper SJ
    Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine.
    Headache. 2020;60:229-234.
    PubMed     Abstract available

    December 2019
  228. EVANS RW, Burch RC, Frishberg BM, Marmura MJ, et al
    Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline.
    Headache. 2019 Dec 31. doi: 10.1111/head.13720.
    PubMed     Abstract available

  229. RICHMOND L, Schneider RP, Steffel J, Sandor PS, et al
    Case Report: New-Onset Retinal Migraine After Transseptal Catheterization.
    Headache. 2019 Dec 30. doi: 10.1111/head.13732.
    PubMed     Abstract available

  230. SPROUSE BLUM AS, Lavoie B, Haag M, Mawe SM, et al
    No Gastrointestinal Dysmotility in Transgenic Mouse Models of Migraine.
    Headache. 2019 Dec 26. doi: 10.1111/head.13724.
    PubMed     Abstract available

  231. ZHANG N, Houle T, Hindiyeh N, Aurora SK, et al
    Systematic Review: Acupuncture vs Standard Pharmacological Therapy for Migraine Prevention.
    Headache. 2019 Dec 24. doi: 10.1111/head.13723.
    PubMed     Abstract available

  232. MUNJAL S, Singh P, Reed ML, Fanning K, et al
    Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study.
    Headache. 2019 Dec 14. doi: 10.1111/head.13708.
    PubMed     Abstract available

  233. HOUTS CR, Wirth RJ, McGinley JS, Gwaltney C, et al
    Content Validity of HIT-6 as a Measure of Headache Impact in People With Migraine: A Narrative Review.
    Headache. 2019 Dec 6. doi: 10.1111/head.13701.
    PubMed     Abstract available

  234. MINEN MT, Zhou K, Miller L
    A Brief Look at Urgent Care Visits for Migraine: The Care Received and Ideas to Guide Migraine Care in this Proliferating Medical Setting.
    Headache. 2019 Dec 4. doi: 10.1111/head.13717.
    PubMed     Abstract available

  235. TEPPER SJ, Silberstein SD, Rosen NL, Lipton RB, et al
    The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings.
    Headache. 2019 Dec 2. doi: 10.1111/head.13716.
    PubMed     Abstract available

    November 2019
  236. MANSOUR AG, Ahdab R, Daaboul Y, Korjian S, et al
    Vitamin K2 Status and Arterial Stiffness Among Untreated Migraine Patients: A Case-Control Study.
    Headache. 2019 Nov 25. doi: 10.1111/head.13715.
    PubMed     Abstract available

  237. SCHWEDT TJ, Digre K, Tepper SJ, Spare NM, et al
    The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort.
    Headache. 2019 Nov 22. doi: 10.1111/head.13688.
    PubMed     Abstract available

  238. HORNIK CP, Gelfand AA, Szperka CL, Pezzuto T, et al
    Development of a Prospective Real-World Data Clinical Registry of Children and Adolescents With Migraine.
    Headache. 2019 Nov 22. doi: 10.1111/head.13714.
    PubMed     Abstract available

  239. KHAN FA, Mohammed AE, Poongkunran M, Chimakurthy A, et al
    Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience.
    Headache. 2019 Nov 22. doi: 10.1111/head.13713.
    PubMed     Abstract available

  240. OAKES TM, Kovacs R, Rosen N, Doty E, et al
    Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies.
    Headache. 2019 Nov 13. doi: 10.1111/head.13684.
    PubMed     Abstract available

  241. YOM KH, Ricca AM, Ko AC
    Orbital Mass in a Patient With Exacerbation of Chronic Migraine - A Case Report.
    Headache. 2019 Nov 13. doi: 10.1111/head.13698.

  242. DETKE HC, Millen BA, Zhang Q, Samaan K, et al
    Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
    Headache. 2019 Nov 11. doi: 10.1111/head.13691.
    PubMed     Abstract available

  243. WANG R, Nie X, Xu S, Zhang M, et al
    Interrelated Pathogenesis? Neuronal Intranuclear Inclusion Disease Combining With Hemiplegic Migraine.
    Headache. 2019 Nov 8. doi: 10.1111/head.13687.
    PubMed     Abstract available

  244. GONZALEZ-MARTINEZ A, Rodriguez Vazquez E, de la Red Gallego H, Garcia-Azorin D, et al
    Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine.
    Headache. 2019 Nov 6. doi: 10.1111/head.13693.
    PubMed     Abstract available

    A Popperian View on Anti-CGRP Biologics in Migraine.
    Headache. 2019 Nov 6. doi: 10.1111/head.13695.

  246. MICHELS L, Villanueva J, O'Gorman R, Muthuraman M, et al
    Interictal Hyperperfusion in the Higher Visual Cortex in Patients With Episodic Migraine.
    Headache. 2019 Nov 4. doi: 10.1111/head.13646.
    PubMed     Abstract available

  247. WINNER PK, Spierings ELH, Yeung PP, Aycardi E, et al
    Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
    Headache. 2019 Nov 1. doi: 10.1111/head.13654.
    PubMed     Abstract available

  248. TURNER SB, Rende EK, Szperka CL, Hershey AD, et al
    The Development of the Pediatric Migraine Action Plan (PedMAP).
    Headache. 2019;59:1671-1672.

  249. TURNER SB, Rende EK, Pezzuto T, Weaver S, et al
    Pediatric Migraine Action Plan (PedMAP).
    Headache. 2019;59:1871-1873.

  250. LODER EW, Tfelt-Hansen P
    Further Questioning of the Significance of the Gepants: A Response.
    Headache. 2019;59:1831.

  251. NGUYEN J, Hu D
    Further Questioning of the Significance of the Gepants.
    Headache. 2019;59:1829-1830.

    October 2019
  252. LIPTON RB, Munjal S, Brand-Schieber E, Tepper SJ, et al
    Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.
    Headache. 2019 Oct 24. doi: 10.1111/head.13663.
    PubMed     Abstract available

  253. MELHADO EM, Thiers Rister HL, Galego DR, de Oliveira AB, et al
    Allodynia in Menstrually Related Migraine: Score Assessment by Allodynia Symptom Checklist (ASC-12).
    Headache. 2019 Oct 21. doi: 10.1111/head.13677.
    PubMed     Abstract available

  254. CONNELLY M, Sekhon S, Stephens D, Boorigie M, et al
    Enhancing Outpatient Dihydroergotamine Infusion With Interdisciplinary Care to Treat Refractory Pediatric Migraine: Preliminary Outcomes From the Comprehensive Aggressive Migraine Protocol ("CAMP").
    Headache. 2019 Oct 18. doi: 10.1111/head.13685.
    PubMed     Abstract available

  255. SAKAI F, Takeshima T, Tatsuoka Y, Hirata K, et al
    A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
    Headache. 2019 Oct 14. doi: 10.1111/head.13652.
    PubMed     Abstract available

  256. CHEN SP, Eikermann-Haerter K
    How Imaging Can Help Us Better Understand the Migraine-Stroke Connection.
    Headache. 2019 Oct 3. doi: 10.1111/head.13664.
    PubMed     Abstract available

  257. BURCH R
    Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review.
    Headache. 2019 Oct 3. doi: 10.1111/head.13665.
    PubMed     Abstract available

  258. SLAVIN M, Li HA, Frankenfeld C, Cheskin LJ, et al
    What is Needed for Evidence-Based Dietary Recommendations for Migraine: A Call to Action for Nutrition and Microbiome Research.
    Headache. 2019;59:1566-1581.
    PubMed     Abstract available

  259. CHUA AL, Grosberg BM, Evans RW
    Status Migrainosus in Children and Adults.
    Headache. 2019;59:1611-1623.

    September 2019
  260. LEROUX E, Rothrock J
    Triptans for Migraine Patients With Vascular Risks: New Insights, New Options.
    Headache. 2019 Sep 30. doi: 10.1111/head.13656.

  261. SENG EK, Singer AB, Metts C, Grinberg AS, et al
    Does Mindfulness-Based Cognitive Therapy for Migraine Reduce Migraine-Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial.
    Headache. 2019 Sep 26. doi: 10.1111/head.13657.
    PubMed     Abstract available

  262. GUTTA R, Valentini KJ, Kaur G, Farooqi AA, et al
    Management of Childhood Migraine by Headache Specialist vs Non-Headache Specialists.
    Headache. 2019 Sep 26. doi: 10.1111/head.13660.
    PubMed     Abstract available

  263. OZUDOGRU S, Neufeld A, Katz BJ, Baggaley S, et al
    Reduced Visual Quality of Life Associated with Migraine is Most Closely Correlated with Symptoms of Dry Eye.
    Headache. 2019 Sep 26. doi: 10.1111/head.13662.
    PubMed     Abstract available

  264. LEE HH, Chen CC, Ong JR, Lin YF, et al
    Association of rs2651899 Polymorphism in the Positive Regulatory Domain 16 and Common Migraine Subtypes: A Meta-Analysis.
    Headache. 2019 Sep 26. doi: 10.1111/head.13670.
    PubMed     Abstract available

  265. CERIANI CEJ, Wilhour DA, Silberstein SD
    Novel Medications for the Treatment of Migraine.
    Headache. 2019 Sep 26. doi: 10.1111/head.13661.
    PubMed     Abstract available

  266. ROTA E, Zucco R, Guerzoni S, Cainazzo MM, et al
    Migraine Awareness in Italy and the Myth of "Cervical Arthrosis".
    Headache. 2019 Sep 26. doi: 10.1111/head.13679.
    PubMed     Abstract available

  267. KNOL MJ, Loehrer EA, Wen KX, Bos D, et al
    Migraine Genetic Variants Influence Cerebral Blood Flow.
    Headache. 2019 Sep 26. doi: 10.1111/head.13651.
    PubMed     Abstract available

  268. ROTHROCK JF, Adams AM, Lipton RB, Silberstein SD, et al
    FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Headache. 2019 Sep 26. doi: 10.1111/head.13653.
    PubMed     Abstract available

  269. LIPTON RB, Hutchinson S, Ailani J, Reed ML, et al
    Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
    Headache. 2019 Sep 22. doi: 10.1111/head.13642.
    PubMed     Abstract available

  270. RAVN J, Chalmer MA, Oehrstroem EL, Kogelman LJA, et al
    Characterization of Familial and Sporadic Migraine.
    Headache. 2019 Sep 22. doi: 10.1111/head.13640.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.